Statement of Cash Flows (USD $)	12 Months Ended		107 Months Ended
	Feb. 28, 2014	Feb. 28, 2013	Feb. 28, 2014
Cash Flows From Operating Activities
Net loss	$ (757,403)	$ (315,938)	$ (3,324,667)
Items to reconcile net loss to net cash used in operating activities:
Amortization	17,440	0	17,440
Contributions to capital by related parties - expenses	0	0	58,799
Contributions to capital by related party - forgiveness of debt	0	0	38,950
Common shares issued for services	0	0	30
Stock based compensation	0	132,138	346,050
(Increase) decrease in prepaid expenses and deposits	17,707	(4,294)	(4,928)
Increase in accounts payable and accrued liabilities, related party	108,088	0	108,088
Increase (decrease) in accounts payable and accrued liabilities	1,318	(158,850)	222,961
Net cash used in continuing operations	(612,850)	(346,944)	(2,537,277)
Net cash provided by (used in) discontinued operations	240,623	(290,677)	45,669
Net cash used in operating activities	(372,227)	(637,621)	(2,491,608)
Cash Flows From Investing Activities
Acquisition of SlickX and Flawsome	(50,000)	0	(50,000)
Capitalized website and website development costs	(102,300)	0	(102,300)
Net cash used in continuing investing activities	(152,300)	0	(152,300)
Net cash provided (used) in discontinued investing activities	0	891,965	(53,135)
Net cash provided by (used in) investing activities	(152,300)	891,965	(205,435)
Cash Flows From Financing Activities
Proceeds from issuance of promissory notes	150,000	0	855,000
Principal payments on promissory notes	(200,000)	0	(200,000)
Common shares returned to treasury	0	0	(5,000)
Proceeds from issuance of common stock	75,000	0	2,060,000
Cash provided by (used in) financing activities	25,000	0	2,710,000
Increase (decrease) in cash and cash equivalents	(499,527)	254,344	12,957
Cash and cash equivalents, beginning of period	512,484	258,140	0
Cash and cash equivalents, end of period	12,957	512,484	12,957
Noncash investing activity
Capitalized website and website development costs	196,500	0	196,500
Apricus Biosciences, Inc. common stock received in consideration for termination of merger agreement	$ 0	$ 1,000,000	$ 1,000,000